Fig. 1.
Fig. 1. Screening of HLA A*2402–binding candidate peptides from amino acid sequences of EBV proteins for CD8+ T-cell stimulation by ELISPOT assay. / Polyclonal EBV-specific CD8+ T cells (1 × 105) established from PBMCs of 4 EBV-seropositive and HLA A24–positive donors were cocultured with T2-A24 cells (5 × 104) in wells in the presence of each peptide at a final concentration of 10 μM. When the spots were too many to count, 1 × 104 CD8+ T cells were used as responder cells and the numbers of spots were shown after multiplication by 10. We used 3 known EBV epitopes (nos. 43-45) and an HLA A24–restricted HIV-specific CD8+ T-cell epitope as control peptides. Each bar represents the average number of spots in duplicate wells.

Screening of HLA A*2402–binding candidate peptides from amino acid sequences of EBV proteins for CD8+ T-cell stimulation by ELISPOT assay.

Polyclonal EBV-specific CD8+ T cells (1 × 105) established from PBMCs of 4 EBV-seropositive and HLA A24–positive donors were cocultured with T2-A24 cells (5 × 104) in wells in the presence of each peptide at a final concentration of 10 μM. When the spots were too many to count, 1 × 104 CD8+ T cells were used as responder cells and the numbers of spots were shown after multiplication by 10. We used 3 known EBV epitopes (nos. 43-45) and an HLA A24–restricted HIV-specific CD8+ T-cell epitope as control peptides. Each bar represents the average number of spots in duplicate wells.

Close Modal

or Create an Account

Close Modal
Close Modal